




PHARMACEUTICAL 2018

Fibrocell Science Inc.
Rank 222 of 342





PHARMACEUTICAL 2018

Fibrocell Science Inc.
Rank 222 of 342

The relative strengths and weaknesses of Fibrocell Science Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Fibrocell Science Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Fibrocell Science Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 33%, being 12% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	17,902
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,425
Liabilities, Non-Current	0
Other Assets	39
Other Compr. Net Income	0
Other Expenses	828
Other Liabilities	5,979
Other Net Income	3,569
Other Revenues	0
Property and Equipment	1,470
Research and Development	6,512
Selling, General and Administrative Expense	6,749

Output Variable	Value in 1000 USD
Assets	19,411
Liabilities	10,404
Expenses	14,089
Revenues	0
Stockholders Equity	9,007
Net Income	-10,520
Comprehensive Net Income	-10,520
Economic Capital Ratio	33%